Latest news with #CGM
Cision Canada
11 hours ago
- Business
- Cision Canada
NiaHealth Taps ex-HelloFresh Exec as First Chief Marketing Officer and Announces Product Expansion as Company Enters Hyper-Growth Phase
Award-winning marketing leader Candy Lee joins NiaHealth amidst accelerating demand, expanded clinical care, and the announcement of significant product expansion as Canada's most comprehensive proactive health platform. TORONTO, July 31, 2025 /CNW/ - NiaHealth, Canada's fastest-growing consumer proactive health company, today announced the appointment of Candy Lee as its first Chief Marketing Officer, marking a major milestone in the company's evolution from emerging startup to national category leader. The announcement today also includes significant product expansion as part of NiaHealth's mission to become Canada's most powerful and comprehensive proactive health platform—launching Continuous Glucose Monitoring (CGM) out of beta, tripling the size of its clinician team, and expanding its core testing panel from 50+ to over 150 biomarkers, now the most complete longevity and healthspan assessment available to Canadians. This news follows a string of major milestones for NiaHealth, including its public debut out of stealth in April, national platform enhancements announced live at Web Summit in May, and the closing of a $5.75M seed fundraise in June led by Golden Ventures, Version One, and other top-tier Canadian tech investors. "Momentum is real, and it's accelerating," said Sameer Dhar, CEO and Co-Founder of NiaHealth. "We've gone from stealth to scale in just a few months—but we've stayed grounded in our mission. Every new test, every clinical consult, every continuous glucose monitor scan is about helping Canadians feel better and live longer. Candy's appointment is a massive leap forward—she's built some of the most loved brands in Canada, and she understands how to meet people where they are. We're not just innovating—we're making proactive care truly accessible." Lee's career spans award-winning marketing and growth leadership at HelloFresh, Homebase, ecobee, and Budweiser—Canada's #1 beer—earning recognition from the Cannes Lions, FastCompany, CMA Awards, Media Innovation Awards, and more. But it was a personal health reckoning that brought her to NiaHealth. "A decade ago, I hit a turning point in my own health," said Candy Lee, Chief Marketing Officer at NiaHealth. "What looked fine on paper spiralled into months of fatigue, inflammation, and unanswered questions. Through that journey, I learned that with the right clinical guidance and proactive biomarker testing, so much of that suffering could have been avoided. What excites me most about NiaHealth isn't just the science or the product—it's the humanity. This is a company that leads with empathy, with clinicians guiding every step. And the opportunity to bring that to millions of Canadians? That's the kind of mission you drop everything for." NiaHealth's platform now includes access to 150+ evidence-backed biomarkers, one-on-one consultations with longevity-trained clinicians, and advanced data integrations with gut microbiome test insights, Vo2Max, DEXA Body Scans, CGMs and fitness wearables like Oura Ring, Fitbit, and Garmin. By combining long-range biomarkers with real-time health data, members gain a full-circle view of their health—before symptoms ever begin. The company has completed nearly 150,000 biomarker tests across the country, with over 90% of members discovering at least one previously unknown—but actionable—health risk, such as pre-diabetes, vitamin D deficiency, or early heart disease indicators. NiaHealth operates in every province except Quebec and offers HSA-eligible plans starting at $299/year. Designed to complement Canada's public healthcare system, NiaHealth supports Canadians between doctor visits—focusing on long-term prevention, lifestyle change, and early intervention. "This next chapter isn't just about scale—it's about impact for Canadians," said Dhar. "We're proving that proactive health can be evidence-based, clinician-guided, and built for real life. That's the future we're working toward, and we're just getting started." About NiaHealth NiaHealth is Canada's leading proactive health platform, helping people live longer, healthier lives through advanced biomarker testing, personalized clinical guidance, and real-time tools like continuous glucose monitoring and fitness wearable integration. With nearly 150,000 biomarker tests completed and plans starting at $299/year, NiaHealth is proudly built in Canada, for Canadians—designed to empower members with long-range insights, early risk detection, and actionable support. Learn more at
Time of India
12 hours ago
- Health
- Time of India
Understanding blood sugar target ranges
Blood sugar levels serve as one amongst the indicators of a person's health, especially for people who are at risk of diabetes and also for the ones with diabetes. To monitor our health, it is important to understand the blood sugar (glucose) levels, how they fluctuate and how food, activities, stress, etc, influence them. Let's deep dive into what blood sugar target ranges are, why they matter, and how they differ depending on various factors. What is blood sugar? Blood sugar refers to the concentration of glucose present in the human bloodstream. Glucose is a simple sugar (monosaccharide) that is the body's primary source of energy. It is when an individual consumes food which consists of carbohydrates, glucose enters the bloodstream. Blood sugar is measured in levels, through which doctors can tell whether it is high, low or normal. Insulin, a hormone produced by the pancreas, helps cells intake glucose from the blood. Blood sugar target ranges Blood sugar targets can vary based on age, health status, type of diabetes, pregnancy, and other individual considerations. The ranges are as follows- 1. Nonpregnant Adults with Diabetes Glycemic Metric Target Range A1C <7.0% (<53 mmol/mol) Preprandial (before meal) glucose 80–130mg/dL (4.4–7.2mmol/L) Peak postprandial (after meal) glucose <180mg/dL (<10.0mmol/L) Time in Range (CGM, 70–180mg/dL) >70% of readings Time Below 70mg/dL <4% of readings Time Below 54mg/dL <1% of readings 2. Children and Adolescents Glycemic Metric Standard Target Comments A1C <7% (<53 mmol/mol) Most children and adolescents A1C Less Stringent <7.5% or <8% If risk of hypoglycemia, limited resources, or other clinical contexts A1C More Stringent <6.5% Select individuals, if attainable without hypoglycemia or undue care burden CGM Time in Range >70% (70–180mg/dL) Use CGM data whenever available 3. Pregnancy (Including Type 1, Type 2 & Gestational Diabetes) Glycemic Metric Target Fasting glucose <95mg/dL (<5.3 mmol/L) 1-hour postprandial <140mg/dL (<7.8 mmol/L) 2-hour postprandial <120mg/dL (<6.7 mmol/L) A1C <6% (<42 mmol/mol) if without hypoglycemia; <7% (<53 mmol/mol) if necessary Sensor TIR (CGM, 63–140mg/dL) >70% of readings (Type 1 recommended) Sensor Time <63mg/dL <4% Sensor Time <54mg/dL <1% Sensor Time >140mg/dL <25% Reference - The tables have been taken from the ADA guidelines 4. Older Adults Generally healthy: Standard adult targets may be used (A1C <7%). These values are based directly on the 2025 ADA Standards of Care Why are blood sugar target ranges important? Staying within target ranges reduces the risk of long-term complications such as nerve, kidney, and eye damage, as well as cardiovascular disease5. Avoiding both low (hypoglycemia) and high (hyperglycemia) blood sugar episodes may prevent acute health crises. What to do when the numbers are not in the normal range? It is important to record blood sugar readings each time they are checked. If the values fall outside the recommended range, it is advisable to consult a healthcare professional for further guidance. Important factors that influence target ranges Age: Older adults may have slightly higher target ranges to reduce the risk of hypoglycemia. Pregnancy: Pregnant women, especially those with gestational diabetes, have stricter targets such as below6: Fasting: ≤ 95 mg/dL 1-hour post-meal: ≤ 140 mg/dL 2-hour post-meal: ≤ 120 mg/dL Type of Diabetes: Diabetes management typically involves a combination of insulin therapy, oral medications, dietary modifications, regular physical activity, and ongoing blood glucose monitoring, tailored to individual needs and medical guidance. Lifestyle and activity level: Physical activity, stress, sleep, and diet may affect glucose levels. Medications: Some medications may raise or lower blood sugar levels. How to monitor blood sugar levels? Finger-prick test by glucometer: A glucometer (also called a blood glucose meter) is a small, portable electronic device used to measure the amount of glucose (sugar) in an individual's blood. It is a key tool for people with diabetes to monitor their blood sugar levels regularly at home. Here's a step-by-step guide on how to use a glucometer. Step 1: Wash and clean your hands Step 2: Prepare the lancing device Step 3: Insert the test strip into the glucometer Step 4: Prick your finger carefully by using the lancing device Step 5: Apply blood to the strip Step 6: After obtaining the blood sample via finger prick, gently apply a sterile cotton ball or gauze to the puncture site to stop the bleeding through slight pressure. Record the result of the test immediately to ensure accuracy and traceability of the data collected. (WHO) Step 7: Dispose of the materials like used strip, cotton, used lancet etc. safely 2. Continuous Glucose Monitors (CGMs): Provide real-time readings throughout the day. This is helpful for Type 1 diabetics or those with fluctuating levels. 3. HbA1c test: This test measures average blood sugar over 2-3 months. Blood sugar target ranges should be considered when monitoring an individual's overall health. Careful monitoring and judicious maintenance of blood sugar target ranges are essential for managing diabetes and supporting long-term health. Whether someone is living with diabetes, at risk, or just health-conscious, monitoring their glucose levels and striving to stay within the optimal range is a wise step toward a healthier life. Always consult a healthcare professional to set personalised targets and build an effective management plan. References - Seshiah, V., et al. (2023). Diagnosis and management of gestational diabetes mellitus guidelines by DIPSI (Revised). International Journal of Diabetes in Developing Countries, 43(4), 485–501
National Post
a day ago
- Health
- National Post
Ontario Expands Access to Dexcom G7 CGM Under the Ontario Drug Benefit (ODB) Program
New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. Article content BURNABY, British Columbia — Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, applauds the Ontario government for its recent decision to include the Dexcom G7 Continuous Glucose Monitoring (CGM) System as part of the Ontario Drug Benefit (ODB) program for eligible Ontarians who manage their diabetes with insulin.* Article content Article content Diabetes Canada estimates that 1.7 million people in Ontario are living with diabetes in 2024, with a significant portion requiring insulin for either type 1 or type 2 diabetes 1. This highlights a broad need for support across both types of diabetes for insulin therapy optimization. Article content This coverage expansion will grant access to Dexcom G7 to a broader population and make Dexcom G7 now the most covered CGM on government-funded programs in Ontario †,2 for people on insulin through the following programs: Article content Ontario Drug Benefit (ODB) Article content – for eligible residents on insulin aged 65+ or earlier if they: Article content Live in a long-term care home, home for special care, or Community Home for Opportunity Are 24 or under without private insurance (OHIP+) Receive professional home and community care Get benefits from Ontario Works or ODSP Are enrolled in the Trillium Drug Program Article content – for individuals with type 1 diabetes who meet the eligibility criteria. Article content Private Insurance Article content – most private insurance plans cover Dexcom G7 for anyone on insulin. Article content – for eligible First Nations and Inuit clients on insulin. Article content 'This announcement represents a significant step forward for people managing diabetes in Ontario and their healthcare providers with more equitable access to Dexcom's life-changing CGM technology,' says André Côté, Vice President and General Manager of Dexcom Canada. 'By expanding coverage for Dexcom G7 under ODB, Ontario is recognizing the value of the #1 preferred glucose sensor by Canadian endocrinologists ‡, 3 for the management of insulin-using patients.' Article content Dexcom G7 is the most accurate CGM with clinically proven outcomes §,2 including lowering A1C, reducing hyper-and hypoglycemia, and increasing time in range for people with type 1 or type 2 diabetes 4-8. Featuring several unique alerts supporting safer insulin therapy, this increased access to Dexcom G7 is welcome news for both healthcare providers and their patients using insulin. Article content 'As an endocrinologist, I've seen firsthand how continuous glucose monitoring has transformed diabetes management,' says Dr. Alexander Abitbol, Endocrinologist & Assistant Medical Director, LMC Healthcare. 'Managing diabetes is very personal, and being able to offer patients a choice on the most appropriate CGM technology with features tailored to help them meet their individualized care goals is critical.' Article content Dexcom G7 allows individuals to easily see their glucose levels in real-time to make more informed insulin treatment decisions. Users can see directly how medications affect their levels and gain insights on what keeps their levels stable, empowering them to learn what works in order to feel their best and stay motivated over time. Article content Discreet and easy to use, Dexcom G7 is the only sensor in Canada to offer these features for insulin therapy optimization and personalization for any lifestyle: Article content As the #1 patient recommended CGM in Canada ††,12, Dexcom G7 delivers both clinical and lifestyle benefits, and now more Ontarians than ever will have access to this technology for their diabetes management. Article content To learn more about Dexcom G7 and the public and private coverage options available, please visit About Dexcom Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in continuous glucose monitoring for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently. Article content _______________________________________ * For ODB eligible persons who are on insulin therapy for diabetes and who have a valid prescription for Dexcom G7 from a physician or nurse practitioner. Limit of 45 Dexcom G7 Sensors per eligible person per 365-day period. Dexcom G7 Receivers are also covered if there is no compatible smart device. For detailed coverage criteria, please visit † Dexcom G7 is the only CGM covered by ODB, ADP, most private insurance & NIHB for people on insulin. Eligibility and coverage vary by policy, plan, and payor. For insurance assistance call Dexcom Canada at 1-844-832-1810 with any questions. ‡ Based on a survey of Canadian Endocrinologists (n=41) § When compared with CGM systems commercially available in Canada as of October, 2023. Sensors worn on the back of the upper arm have been found to be slightly more accurate than sensors worn on the abdomen. || Audible and visual notification of predictive alert at 3.1 mmol/L within 20 minutes. ¶ The Dexcom G7 Sensor is waterproof and may be submerged under eight feet of water for up to 24 hours without failure when properly installed. # Indicated for wear on the back of the upper arm and abdomen for ages 2 years and older or the upper buttocks for ages 2-6 years old. ** Smart device sold separately. To view a list of compatible devices, visit Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. †† Based on a comparison in NPS scores across major CGM brands 1 2 Dexcom, data on file, 2025 3 Q&A, Dexcom Canadian Endos Report Wave 1 2024 4 Beck, RW, et al. JAMA. 2017;317(4):371-378. 5 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374. 6 Martens T, et al. JAMA. 2021;325(22):2262-2272. 7 Laffel LM, et al. JAMA. 2020;323(23):2388-2396. 8 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-7. 9 Dexcom G7 User Guide. 10 Aly A, et al. Diabetes Technol. Ther. 2024;26(S2): A254-255. 11 Puhr S, et al. Diabetes Technol Ther. 2019;21(4):155-158. 12 DQ&A, Canada Diabetes Connections Patient Panel Report, H1 2024 Article content Article content Article content Article content Article content Contacts Article content Media Contact: Article content Article content Cole Douglas Article content Article content Article content
Yahoo
a day ago
- Health
- Yahoo
Ontario Expands Access to Dexcom G7 CGM Under the Ontario Drug Benefit (ODB) Program
New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. BURNABY, British Columbia, July 30, 2025--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, applauds the Ontario government for its recent decision to include the Dexcom G7 Continuous Glucose Monitoring (CGM) System as part of the Ontario Drug Benefit (ODB) program for eligible Ontarians who manage their diabetes with insulin.* Diabetes Canada estimates that 1.7 million people in Ontario are living with diabetes in 2024, with a significant portion requiring insulin for either type 1 or type 2 diabetes1. This highlights a broad need for support across both types of diabetes for insulin therapy optimization. This coverage expansion will grant access to Dexcom G7 to a broader population and make Dexcom G7 now the most covered CGM on government-funded programs in Ontario†,2 for people on insulin through the following programs: Ontario Drug Benefit (ODB) – for eligible residents on insulin aged 65+ or earlier if they: Live in a long-term care home, home for special care, or Community Home for Opportunity Are 24 or under without private insurance (OHIP+) Receive professional home and community care Get benefits from Ontario Works or ODSP Are enrolled in the Trillium Drug Program Assistive Devices Program (ADP) – for individuals with type 1 diabetes who meet the eligibility criteria. Private Insurance – most private insurance plans cover Dexcom G7 for anyone on insulin. Non-Insured Health Benefits (NIHB) – for eligible First Nations and Inuit clients on insulin. "This announcement represents a significant step forward for people managing diabetes in Ontario and their healthcare providers with more equitable access to Dexcom's life-changing CGM technology," says André Côté, Vice President and General Manager of Dexcom Canada. "By expanding coverage for Dexcom G7 under ODB, Ontario is recognizing the value of the #1 preferred glucose sensor by Canadian endocrinologists‡, 3 for the management of insulin-using patients." Dexcom G7 is the most accurate CGM with clinically proven outcomes§,2 including lowering A1C, reducing hyper-and hypoglycemia, and increasing time in range for people with type 1 or type 2 diabetes4-8. Featuring several unique alerts supporting safer insulin therapy, this increased access to Dexcom G7 is welcome news for both healthcare providers and their patients using insulin. "As an endocrinologist, I've seen firsthand how continuous glucose monitoring has transformed diabetes management," says Dr. Alexander Abitbol, Endocrinologist & Assistant Medical Director, LMC Healthcare. "Managing diabetes is very personal, and being able to offer patients a choice on the most appropriate CGM technology with features tailored to help them meet their individualized care goals is critical." Dexcom G7 allows individuals to easily see their glucose levels in real-time to make more informed insulin treatment decisions. Users can see directly how medications affect their levels and gain insights on what keeps their levels stable, empowering them to learn what works in order to feel their best and stay motivated over time. Discreet and easy to use, Dexcom G7 is the only sensor in Canada to offer these features for insulin therapy optimization and personalization for any lifestyle: Predictive Urgent Low Soon|| alert that can warn in advance of severe hypoglycemia9 Delay 1st High alert after a meal that may help reduce insulin stacking10,11 Waterproof sensor¶ Fast 30-minute sensor warm-up time Multiple sensor wear locations# Direct to Apple Watch functionality**– user can see glucose numbers right on their wrist As the #1 patient recommended CGM in Canada††,12, Dexcom G7 delivers both clinical and lifestyle benefits, and now more Ontarians than ever will have access to this technology for their diabetes management. To learn more about Dexcom G7 and the public and private coverage options available, please visit About Dexcom Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in continuous glucose monitoring for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently. Dexcom. Discover what you're made of. For more information, visit Category: IR _______________________________________ * For ODB eligible persons who are on insulin therapy for diabetes and who have a valid prescription for Dexcom G7 from a physician or nurse practitioner. Limit of 45 Dexcom G7 Sensors per eligible person per 365-day period. Dexcom G7 Receivers are also covered if there is no compatible smart device. For detailed coverage criteria, please visit † Dexcom G7 is the only CGM covered by ODB, ADP, most private insurance & NIHB for people on insulin. Eligibility and coverage vary by policy, plan, and payor. For insurance assistance call Dexcom Canada at 1-844-832-1810 with any questions. ‡ Based on a survey of Canadian Endocrinologists (n=41) § When compared with CGM systems commercially available in Canada as of October, 2023. Sensors worn on the back of the upper arm have been found to be slightly more accurate than sensors worn on the abdomen. || Audible and visual notification of predictive alert at 3.1 mmol/L within 20 minutes. ¶ The Dexcom G7 Sensor is waterproof and may be submerged under eight feet of water for up to 24 hours without failure when properly installed. # Indicated for wear on the back of the upper arm and abdomen for ages 2 years and older or the upper buttocks for ages 2-6 years old. ** Smart device sold separately. To view a list of compatible devices, visit Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. †† Based on a comparison in NPS scores across major CGM brands 1 2 Dexcom, data on file, 2025 3 Q&A, Dexcom Canadian Endos Report Wave 1 2024 4 Beck, RW, et al. JAMA. 2017;317(4):371-378. 5 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374. 6 Martens T, et al. JAMA. 2021;325(22):2262-2272. 7 Laffel LM, et al. JAMA. 2020;323(23):2388-2396. 8 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-7. 9 Dexcom G7 User Guide. 10 Aly A, et al. Diabetes Technol. Ther. 2024;26(S2): A254-255. 11 Puhr S, et al. Diabetes Technol Ther. 2019;21(4):155-158. 12 DQ&A, Canada Diabetes Connections Patient Panel Report, H1 2024 View source version on Contacts Media Contact: Cole DouglasCdouglas@ 416.460.5480 Investor Contact: investor-relations@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Daily Mirror
2 days ago
- Entertainment
- Daily Mirror
What is Chantaines in The Assassin?
The Prime Video series has been gripping viewers The Assassin only landed last week, but the show has already shot to the top of Prime Video in the UK as audiences binge through the thriller. The six-part series follows retired hit woman Julie Green (played by Keeley Hawes), who is pulled onto one last job - but there's more to it than she could ever have imagined. Adding another layer of complexity is that Julie's estranged son Edward Green (Freddie Highmore) has come to visit her after several years. What starts out as a run-of-the-mill job turns into something much bigger with Julie and Edward going on the run as they try to uncover the truth. The series from the makers of The Tourist and The Missing has left fans with many questions and surprise after realising one cast member's iconic role - here's the answer to two of the biggest mysteries of the show. What is Chantaines in The Assassin? The big mystery of the show was the word 'Chantaines' after Kayla Cross (Shalom Brune-Franklin) asked right from episode one what it all meant. Chantaines was the name of Kayla's mother's French poodle, which was in turn was named after a marmalade that she'd become obsessed with. However, Chantaines was actually the codeword for the hit Kayla's parents ordered on a French arms dealer Jean-Luc Bertrand. Aaron Cross (Alan Dale) and his wife ordered the hit to 'erase' Jean-Luc after they borrowed money from him when their lucrative company CGM fell on hard times during its early days. Details of Chantaines were in Kayla's mother's suicide note, which Aaron had tried to keep from his children. Sadly, the guilt of the ordered murder pushed her to take her own life, while Aaron was left living with their decision. Julie confirmed she had been assigned to the French Poodle hit, which also had another shocking twist and coincidence to it. Who is Edward's dad in The Assassin? There were plenty of red herrings before Edward's father was finally revealed. Edward's father was Jean-Luc, who was killed by Julie and the same arms dealer the Cross family had ordered the hit on. Julie had believed the house was empty apart from the arms dealer and was shocked to discover Jean-Luc's family, including his wife Marie (Gina Gershon) and infant son Florent were also in the property. Marie revealed to Edward that Julie had shot her in the head after killing Jean-Luc, believing she was dead. Julie had then heard Florent crying out and had kidnapped him, hoping to provide the child with a better and less dangerous life. So, she had lied to Edward/Florent to protect him from the truth. Despite getting shot, Marie had survived and remained in a coma before eventually coming to. She had vowed to take revenge on Julie and be reunited with her surrogate son Florent. Marie also confirmed she wasn't Edard's mother and never wanted children, so Jean-Luc had used a surrogate to have a child. The show ended with Edward/Florent going off to meet his real mother with Julie accompanying him and Kayla.
